Comparisons of Rosiglitazone Versus Pioglitazone Monotherapy Introduction and Associated Health Care Utilization in Medicaid-Enrolled Patients with Type 2 Diabetes Mellitus

Clinical Therapeutics

Volumn 29, Issue 6 PART 1, 2007, Pages 1306-1315

  Balkrishnan, Rajesh ^a   Arondekar, Bhakti V ^b   Camacho, Fabian T ^c   Shenolikar, Rahul A ^a   Horblyuk, Ruslan ^b   Anderson, Roger T ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

diabetes mellitus; Medicaid; pioglitazone; rosiglitazone; thiazolidinediones

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ADULT; ARTICLE; CONSULTATION; COST OF ILLNESS; EMERGENCY WARD; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MONEY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; UNITED STATES; COMPARATIVE STUDY; ECONOMICS; EMERGENCY HEALTH SERVICE; EPIDEMIOLOGY; HEALTH SERVICE; MIDDLE AGED; STATISTICAL MODEL; STATISTICS; TIME; TREATMENT OUTCOME;

ADULT; DIABETES MELLITUS, TYPE 2; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEALTH CARE SURVEYS; HEALTH SERVICES; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; LINEAR MODELS; MALE; MEDICAID; MIDDLE AGED; MULTIVARIATE ANALYSIS; NORTH CAROLINA; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 38449088928     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.06.019     Document Type: Article

References (31)

1. American Diabetes Association. Diabetes statistics. Available at:. http://www.diabetes.org/diabetes-statistics.jsp Accessed October 1, 2006
2. National diabetes Fact sheet: National estimates and general information on diabetes in the United States (2004), Centers For Disease Control and Prevention, Atlanta, Ga. http://www.diabetes.org/diabetes-statistics/national-diabetes-fact-sheet .jsp Accessed October 1, 2006
3. Amos A., McCarty D., and Zimmet P. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010. Diabet Med 14 Suppl 5 (1997) S1-S85
4. Hogan P., Dall T., Nikolov P., and American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 26 (2003) 917-932
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329 (1993) 977-986
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). [published correction appears in Lancet. 1999;354:602]. Lancet 352 (1998) 837-853
7. Renders C., Valk G., Griffin S., et al. Interventions to improve the management of diabetes in primary care, outpatient, and community settings: A systematic review. Diabetes Care 24 (2001) 1821-1833
8. O'Connor P., Spann S., and Woolf S. Care of adults with type 2 diabetes mellitus. A review of the evidence. J Fam Pract. 47 Suppl 5 (1998) S13-S22
9. Stratton I., Adler A., Neil H., et al. Association of glycaernia with rnacrovascular and rnicrovascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321 (2000) 405-412
10. Turner R., Cull C., Frighi V., Holman R., and UK Prospective Diabetes Study (UKPDS) Group. Glycernic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 281 (1999) 2005-2012
11. Wagner E., Sandhu N., Newton K., et al. Effect of improved glycemic control on health care costs and utilization. JAMA 285 (2001) 182-189
12. Smedley B., Stith A., Nelson A., and Institute of Medicine (US) Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care. Unequal Treatment Confronting Racial and Ethnic Disparities in Healthcare (2002), National Academy Press, Washington, DC
13. Saaddine J., Engelgau M., Beckles G., et al. A diabetes report card for the United States: Quality of care in the 1990s. Ann Intern Med 136 (2002) 565-574
14. Owens D. Thiazolidinediones: A pharmacological overview. Clin Drug Invest 22 (2002) 485-505
15. Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther 26 (2004) 177-190
16. Bell D. Type 2 diabetes mellitus: What is the optimal treatment regimen?. Am J Med. 116 Suppl 5A (2004) 235-295
17. Yanagawa T., Araki A., Sasamoto K., et al. Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes. Metabolism 53 (2004) 353-357
18. Rosenstock J., Goldstein B., Vinik A., et al., RESULT Study Group. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): The Rosiglitazone Early vs Sulphonylurea Titration (RESULT) study. Diabetes Obes Metab. 8 (2006) 49-57
19. Beale S., Bagust A., Shearer A., et al. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK. PharmacoEconomics 24 Suppl 1 (2006) 21-34
20. Coyle D., Palmer A., and Tam R. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. PharmacoEconomics 20 Suppl 1 (2002) 31-42
21. Balkrishnan R., Rajagopalan R., Shenolikar R., et al. Outcomes associated with introduction of thiazolidinedione therapy in Medicaid enrolled patients with type 2 diabetes: An updated and expanded retrospective analysis. Curr Med Res Opin 22 (2006) 551-559
22. Piette J., Heisler M., and Wagner T. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care 27 (2004) 384-391
23. Pierre J., Wagner T., Potter M., and Schillinger D. Health insurance status, cost-related medication under-use, and outcomes among diabetes patients in three systems of care. Med Care 42 (2004) 102-109
24. Kahn S., Haffner S., Heise M., et al., ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [published correction appears in N Engl J Med. 2007;356:1387-1388]. N Engl J Med. 355 (2006) 2427-2443
25. Balkrishnan R., Norwood G., and Anderson A. Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a Medicaid population of asthmatic patients. Clin Tker 20 (1998) 567-580
26. Choo P., Rand C., Inui T., et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 37 (1999) 846-857
27. Steiner J., Koepsell T., Fihn S., and Inui T. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 26 (1988) 814-823
28. Balkrishnan R., Rajagopalan R., Camacho F., et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: A longitudinal cohort study. Clin Ther 25 (2003) 2958-2971
29. Kennedy P. Estimation with correctly interpreted dummy variables in semilogarithmic equations. Am Econ Rev 71 (1981) 801
30. Diehr P., Yanez D., Ash A., et al. Methods For analyzing health care utilization and costs. Annu Rev Public Health 20 (1999) 125-144
31. Manning W., and Mullahy J. Estimating log models: To transform or not to transform?. J Health Econ. 20 (2001) 461-494